DOV Pharmaceutical, Inc. ("DOV" or the "Company") (Pink Sheets: DOVP.PK) today announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. [click ...
From: www.medicalnewstoday.com
Depression and obesity - DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results For DOV 21,947
Posted by Ruslan Abuzant at 3:56 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment